Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE. |
08-03-04-01 Breast cancer
| Exemestane |
|
Formulary
|
Tablets 25mg Breast cancer. |
 NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
|
| Fulvestrant Faslodex® |
|
Formulary
|
| Prefilled syringe 250mg/5mL |
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
|
| Letrozole |
|
Formulary
|
Tablets 2.5mg Breast cancer. |
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
|
|
| Olaparib |
|
Formulary
|
|
NICE TA1040: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy |
|
| Tamoxifen |
|
Formulary
|
Tablets 10mg, 20mg For treating premenopausal women at high risk of breast cancer unless they have a past history or may be at increased risk of thromboembolic disease or endometrial cancer. |
|
NICE CG164: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
|
|
Links
Drug interactions, genetic variants and variability in clinical response (MHRA drug safety update Nov 2010)- LSC Breast Chemotherapy Protocols
- MHRA Drug Safety Update June 2021: CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib): reports of interstitial lung disease and pneumonitis, including severe cases
- MHRA Drug Safety Update June 2021: CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib): reports of interstitial lung disease and pneumonitis, including severe cases
- NHSE: National Cancer Drugs Fund list
- NICE CG164: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
- NICE CG164: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
- NICE CG81: Advanced breast cancer: diagnosis and treatment
- NICE NG101: Early and locally advanced breast cancer: diagnosis and management
- NICE NG101: Early and locally advanced breast cancer: diagnosis and management
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkin’s lymphoma: diagnosis and management
- NICE TA1040: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
- NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
- NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
- NICE TA295: Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy
- NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
- NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
- NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
- NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
- NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
- NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
- NICE TA836:Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy